Stem Cells Market Trends 2010: Drug Discovery/Toxicity Screening and Regenerative Medicine

Publisher: Select Biosciences
Published: April 2010
Pages: 52

Price:

This market trends report from Select Biosciences presents the results from our latest industry tracking completed in March 2010. The data presented herein are based on primary market surveys from a worldwide respondent pool of industry participants active in the stem cells field. This bottom-up analysis highlights market trends operative and enables the identification of trends vis-a-vis the research marketplace, utilization of different classes of stem cells, as well as the penetrance of different research product vendors into specific segments of the stem cells marketplace.

This market report is built using data and analyses from Select Biosciences continual industry tracking of this marketplace and our analysis of this space provides up-to-date qualitative and quantitative market metrics. Primary Market Data Provide a Comprehensive and Bottom-Up Picture of the marketplace for the utilization of stem cells for drug discovery/toxicity screening efforts as well as research for regenerative medicine applications.

Specific Topics Covered in this Trends Report:

Primary and Up-to-Date Market Survey from a Worldwide Cross Section of the Stem Cells Industry Participants
Quantitative Market Penetration of Vendors Offering Products (in various segments) to the Stem Cells Research Community
Utilization Trends of Different Classes of Stem Cells for Drug Discovery/Toxicity Screening and Associated Trends
Penetrance of hESCs and iPSCs in Drug Discovery/Toxicity Screening
Currently Commercialized Products and Services Utilizing Stem Cells for Drug Discovery/Toxicity Screening
Activities Utilizing Stem Cells for Research Efforts in Regenerative Medicine
Cardiovascular Disease and CNS Disease Research Trends vis-a-vis Utilization of Stem Cells

This data-driven characterization of the stem cells market landscape is a hands-on document that can be used for competitive benchmarking, business planning, and strategy development-all the data that have been collected in this industry analysis are presented and they form the basis for the conclusions drawn throughout the market report presented in a format enabling "drag-and-drop" into business presentations or business plans.

Report Table of Contents (TOC) [Click Here to Download PDF File]

For enquiries about this market report, please contact Kathy Gray at Kathy.Gray@Selectbiosciences.com

Conference News

New ELA Blog
In the run up to European Lab Automation 2013, we’ll be sharing some interesting news and insights around the event on our new blog - http://tinyurl.com/aafeu9f . We’d be delighted if you’d like to comment on some of our blog posts, adding your own thoughts and generally become a valued part of the conversation!

'Illuminating Cellular Pathways through Combining High Content Assays with the BDA Method'
Keynote talk to be delivered by Dr Hakim Djaballah, Director, Memorial Sloan Kettering Cancer Center 'Illuminating Cellular Pathways through Combining High Content Assays with the BDA Method: Too Much Hay and Very Few Needles in Random RNAi Screening Stacks' at the DDA: High-content Screening & Cell Based Assays conference track at ELA. For the full agenda, please view: http://bit.ly/YSUu0P

5 Reasons Not to Miss ELA 2013
We understand that staying up-to-date on the latest technologies boosting efficiency and effectiveness in the lab can be challenging. That’s exactly why we created ELA. Our latest blog entry - http://bit.ly/15HpwvN - highlights five key reasons not to miss this year’s event, all based on feedback we’ve received from past attendees.

Optimising NGS workflows – an interview with Dr Mike Quail, Team Leader at the Sanger Institute
In this week's blog entry - http://bit.ly/15HpwvN - Dr Quail gives us some insight into the current advances being made in NGS, as well as some of the challenges still facing the optimisation of NGS pipelines. Dr Quail will be speaking at ELA 2013 about the new NGS applications being developed at the Sanger Institute, as well as some of improvements his team are making to sequencing protocols.

Trends at the forefront of liquid handling and lab automation
This week we caught up with Joe Liscouski, Executive Director at the Institute for Laboratory Automation (ILA) in MA, USA, to find out more about how the use of liquid handling has evolved over the last decade and to gain some insight into what we can expect next.

Harnessing the Great Promise of Microfluidics - an interview with Holger Becker
Dr Holger Becker, Chief Scientific Officer of microfluidic ChipShop GmbH, discusses the great potential of microfluidics in our latest blog entry – http://bit.ly/15HpwvN. Dr Becker will also be running a training course on ‘Microfluidics from the Concept to a Product: Technologies, Applications and Commercialisation Strategies’ at ELA on June 5th http://bit.ly/13ovJPE